Primary radiation therapy has become an accepted alternative to mastectomy for @entity1 with early @entity0 . In order to improve the results of this treatment, we performed an analysis of failure on 366 clinical Stage I or II invasive @entity0 treated with primary radiation therapy. With a median follow-up of 52 months, there have been 30 recurrences in the treated breast, for a 5 year actuarial local recurrence rate of 9%. The recurrence rate was much higher for @entity1 having less-than-excisional biopsy than for those undergoing excisional biopsy (35% vs. 7%, p less than 0.0001). Failures in the treated breast have been categorized as: true recurrence (TR), directly at the site of the primary; marginal miss (MM), at the edge of the boosted volume; and elsewhere in the breast (E). For @entity1 having excisional biopsy, the actuarial probability of a true recurrence at 5 years was 4%. The risk of a true recurrence was related to the dose given to the primary site with rare true recurrences seen with doses greater than 6000 rad. The probability of a marginal miss at 5 years was 4%, and was not related to the dose or volume of the boost used. The probability of a recurrence elsewhere in the breast at 5 years was 1%. In @entity1 treated with excisional biopsy and a total primary dose over 6000 rad, the probability of a local recurrence at 5 years was 4 and 10% for clinical Stage I and II @entity1 respectively. These results indicate that primary radiation therapy provides a high likelihood of @entity5 control and our analysis of failure suggests methods for decreasing each type of local recurrence.

Breast relapse following primary radiation therapy for early XXXX . I. Classification, frequency and salvage.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['local tumor'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast carcinomas']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
